Share Email Print

Proceedings Paper

Studies of vascular acting photosensitizer Tookad for the photodynamic therapy of prostate cancer
Author(s): Zheng Huang; Qun Chen; Dominique Blanc; Fred W. Hetzel
Format Member Price Non-Member Price
PDF $14.40 $18.00

Paper Abstract

In this pre-clinical study, photodynamic therapy (PDT) mediated with a vascular acting photosensitizer Tookad (palladium-bacteriopheophorbide) is investigated as an alternative treatment modality for the ablation of prostate cancer. Canine prostate was used as the animal model. PDT was performed by interstitially irradiating the surgically exposed prostates with a diode laser (763 nm) to activate the IV infused photosensitizer. The effects of drug dose, drug-light interval, and light fluence rate on PDT efficacy were evaluated. The prostates and adjacent tissues were harvested at one-week post PDT and subjected to histopathological examination. The dogs recovered well with little or no urethral complications. Urinalysis showed trace blood. Histological examination showed minimal damage to the prostatic urethra. These indicated that the urethra was well preserved. PDT induced prostate lesions were characterized by marked hemorrhagic necrosis with a clear demarcation. Maximum lesion volume of ~3 cm3 could be achieved with a single 1-cm diffuser fiber at a dose level of 1 mg/kg and 200 J/cm, suggesting the therapy is very effective in ablating prostatic tissue. PDT induced lesion could reach the capsule layers but adjacent tissues were well preserved. The novel photosensitizer is a vascular drug and cleared rapidly from the circulation. Light irradiation can be performed during drug infusion thereby eliminating waiting time. The novel vascular acting photosensitizer Tookad-mediated PDT could provide an effective alternative to treat prostate cancer.

Paper Details

Date Published: 18 January 2005
PDF: 7 pages
Proc. SPIE 5630, Optics in Health Care and Biomedical Optics: Diagnostics and Treatment II, (18 January 2005); doi: 10.1117/12.570280
Show Author Affiliations
Zheng Huang, HealthONE Alliance (United States)
Qun Chen, HealthONE Alliance (United States)
Dominique Blanc, Steba-Biotech (France)
Fred W. Hetzel, HealthONE Alliance (United States)

Published in SPIE Proceedings Vol. 5630:
Optics in Health Care and Biomedical Optics: Diagnostics and Treatment II
Britton Chance; Mingzhe Chen; Arthur E. T. Chiou; Qingming Luo, Editor(s)

© SPIE. Terms of Use
Back to Top